Last reviewed · How we verify
Vaccine anti-H1N1
This vaccine induces an immune response against the H1N1 influenza virus.
This vaccine induces an immune response against the H1N1 influenza virus. Used for Prevention of H1N1 influenza.
At a glance
| Generic name | Vaccine anti-H1N1 |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
By stimulating the body's immune system to produce antibodies and immune cells that recognize and attack the H1N1 virus, this vaccine helps to prevent infection and reduce the severity of symptoms.
Approved indications
- Prevention of H1N1 influenza
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Efficacy Safety Study of Flu Vaccine in Immunodepression Patients (PHASE3)
- Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff. (PHASE4)
- Development of Childhood Anti-Influenza Immunity (PHASE4)
- Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaccine anti-H1N1 CI brief — competitive landscape report
- Vaccine anti-H1N1 updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI